{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:12:27Z","timestamp":1792015947031,"version":"4.4.0"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,11,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with yttrium-90 (\n                      <jats:sup>90<\/jats:sup>\n                      Y)\u2013ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma in first remission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Patients with CD20\n                      <jats:sup>+<\/jats:sup>\n                      stage III or IV follicular lymphoma, who achieved a complete response (CR)\/unconfirmed CR (CRu) or partial response (PR) after first-line induction treatment, were randomly assigned to receive\n                      <jats:sup>90<\/jats:sup>\n                      Y-ibritumomab tiuxetan (rituximab 250 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on day \u22127 and day 0 followed on day 0 by\n                      <jats:sup>90<\/jats:sup>\n                      Y-ibritumomab tiuxetan 14.8 MBq\/kg; maximum of 1,184 MBq) or no further treatment (control). The primary end point was progression-free survival (PFS), which was calculated from the time of random assignment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 414 patients (consolidation, n = 208; control, n = 206) were enrolled at 77 centers.\n                      <jats:sup>90<\/jats:sup>\n                      Y-ibritumomab tiuxetan consolidation significantly prolonged median PFS (after a median observation time of 3.5 years) in all patients (36.5 v 13.3 months in control arm; hazard ratio [HR] = 0.465; P &lt; .0001) and regardless of whether patients achieved PR (29.3 v 6.2 months in control arm; HR = 0.304; P &lt; .0001) or CR\/CRu (53.9 v 29.5 months in control arm; HR = 0.613; P = .0154) after induction treatment. Median PFS with consolidation was prolonged in all Follicular Lymphoma International Prognostic Index risk subgroups. After\n                      <jats:sup>90<\/jats:sup>\n                      Y-ibritumomab tiuxetan consolidation, 77% of patients in PR after induction converted to CR\/CRu, resulting in a final CR rate of 87%. The most common toxicity with\n                      <jats:sup>90<\/jats:sup>\n                      Y-ibritumomab tiuxetan was hematologic, and grade 3 or 4 infections occurred in 8% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Consolidation of first remission with\n                      <jats:sup>90<\/jats:sup>\n                      Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging PFS by 2 years and resulting in high PR-to-CR conversion rates regardless of type of first-line induction treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2008.17.2015","type":"journal-article","created":{"date-parts":[[2008,10,14]],"date-time":"2008-10-14T23:34:52Z","timestamp":1224027292000},"page":"5156-5164","source":"Crossref","is-referenced-by-count":392,"title":["Phase III Trial of Consolidation Therapy With Yttrium-90\u2013Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma"],"prefix":"10.1200","volume":"26","author":[{"given":"Franck","family":"Morschhauser","sequence":"first","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achiel","family":"Van Hoof","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Soubeyran","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Tilly","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Huijgens","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"d\u2019Amore","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Gonzalez","family":"Diaz","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sebban","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus H.J.","family":"van Oers","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van Putten","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Bischof-Delaloye","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama","family":"Rohatiner","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhlmann","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hagenbeek","sequence":"additional","affiliation":[{"name":"From the Centre Hospitalier Universitaire, Lille; Institut Bergoni\u00e9, Bordeaux; Centre Henri Becquerel, Rouen; Centre L\u00e9on B\u00e9rard, Lyon; Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France; Christie Hospital and University of Manchester, Manchester; St Bartholomew's Hospital, London, United Kingdom; General Hospital St-Jan, Brugge, Belgium; Azienda Universitaria Ospedaliera S. Giovanni Battista, Torino; Azienda Ospedaliera Pisana, Pisa; Institute of Hematology \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2004.06.002"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311253292203"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Salles GA, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up. Blood 110:243a,2007-244a,  (abstr 792)","DOI":"10.1182\/blood.V110.11.792.792"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.170"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3920"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-013193"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0372-y"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500376076"},{"key":"R19","unstructured":"Czuczman MS, Emmanouilides CE, Witzig T, et al: Multivariate analysis of prognostic factors correlated with response to 90Y-ibritumomab tiuxetan (Zevalin) radioimmunohterapy for non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 21:266a,2002,  (abstr 1062)"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2007.359"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008205619617"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5957"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Harris NL: Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group). Ann Oncol 8:11,1997-16,  (suppl 2)","DOI":"10.1093\/annonc\/8.suppl_2.S11"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.4711"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.803"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.562"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.8198"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Jankowitz RC, Foon KA, DeMonaco NA, et al: Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line tretament for follicular lymphoma (FL). J Clin Oncol 25:442s,2007,  (suppl; abstr 8005)","DOI":"10.1200\/jco.2007.25.18_suppl.8005"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.579"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.043"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0207-0"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.12.008"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Hochster HS, Weller E, Gascoyne RD, et al: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106:106a,2005,  (abstr 349)","DOI":"10.1182\/blood.V106.11.349.349"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.17.2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:23:46Z","timestamp":1653510226000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.17.2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,10]]},"references-count":36,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2008,11,10]]}},"alternative-id":["10.1200\/JCO.2008.17.2015"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.17.2015","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1127123.601957","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1127123.584266","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,10]]}}}